KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Employees

133

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-06-10	2,268.00 ¥	0.00%	2,700
26-06-09	2,268.00 ¥	0.00%	1,200
26-06-08	2,268.00 ¥	0.00%	600

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-10 EDT			5-day change	1st Jan Change
2,268.00 ^JPY	0.00%		0.00%	+78.44%

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-24	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI

Market Cap	1.14B 7.09M 6.12M 5.64M 5.28M 9.9M 674M 10.05M 66.62M 25.97M 328M 26.6M 26.04M	P/E Ratio 2009	3.96x	P/E Ratio 2010	13.8x
Enterprise Value	2.04B 12.76M 11.02M 10.16M 9.51M 17.82M 1.21B 18.09M 120M 46.76M 590M 47.9M 46.88M	EV / Sales 2009	0.43x	EV / Sales 2010	0.55x
Free-Float	3.88%	Yield 2009	2.68%	Yield 2010	2.38%

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-24	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI
02-09	Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion.	CI
02-08	Denka Unit Launches Tender Offer for Kainos Laboratories	MT
02-06	Denka Co Ltd - Will launch tender offer for Kainos shares	RE
24-12-18	Italian stationery maker FILA cuts stake in listed Indian unit DOMS	RE
22-03-13	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
22-02-24	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI
21-11-25	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	CI
21-11-25	KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	CI
21-11-25	KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	CI
21-11-24	KAINOS Laboratories, Inc. authorizes a Buyback Plan.	CI
20-11-25	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	CI

Current month	+0.18%
1 month	-0.22%
3 months	-0.53%
6 months	+80.29%
Current year	+78.44%

KAINOS Laboratories, Inc. Stock

Stocks

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Valuation: KAINOS Laboratories, Inc.

Chart: KAINOS Laboratories, Inc.

Latest news : KAINOS Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: KAINOS Laboratories, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 week	2,268	2,269
1 month	2,263	2,277
Current year	1,257	2,284
1 year	1,204	2,284
3 years	1,005	2,284
5 years	929	2,284
10 years	488	2,284

Manager	Title	Age	Since
Yukihiro Nagatsu PSD	President	66	2022-03-31
Tsukasa Hayashi ADM	Chief Administrative Officer	64	2016-05-31
Nobuaki Nakano PRN	Corporate Officer/Principal	62	2024-06-30

Director	Title	Age	Since
Yukihiro Nagatsu BRD	Director/Board Member	66	2014-05-31
Tsukasa Hayashi BRD	Director/Board Member	64	2014-05-31
Kenji Kikuchi BRD	Director/Board Member	74	2014-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS LABORATORIES, INC.	0.00%	0.00%	+83.79%	+122.35%	62.99M
GUARDANT HEALTH, INC.	+0.55%	+4.78%	+167.03%	+249.59%	17.45B
BIOMÉRIEUX	-1.74%	-7.00%	-43.82%	-25.79%	9.25B
LANTHEUS HOLDINGS, INC.	+0.19%	+3.51%	+34.29%	+21.62%	6.8B
CARIS LIFE SCIENCES, INC.	-0.17%	+8.98%	-	-	5.08B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.39%	-2.02%	-27.97%	-27.14%	5.06B
DIASORIN S.P.A.	-2.92%	-6.89%	-28.74%	-31.75%	4.08B
ANDON HEALTH CO., LTD.	-1.36%	-13.84%	+68.37%	+62.62%	3.77B
10X GENOMICS, INC.	-0.72%	-7.09%	+176.91%	-50.20%	3.66B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.64%	+0.51%	-16.55%	-41.45%	2.64B
Average	-0.59%	-1.32%	+45.92%	+31.09%	5.79B
Weighted average by Cap.	-0.45%	-0.15%	+63.49%	+74.80%

	2009	2010
Net sales	3.59B 22.44M 19.38M 17.86M 16.72M 31.33M 2.13B 31.82M 211M 82.23M 1.04B 84.22M 82.43M	4.22B 26.31M 22.73M 20.94M 19.6M 36.74M 2.5B 37.31M 247M 96.41M 1.22B 98.75M 96.65M
Net income	168M 1.05M 904K 833K 780K 1.46M 99.52M 1.48M 9.84M 3.84M 48.44M 3.93M 3.85M	101M 633K 547K 504K 472K 884K 60.19M 898K 5.95M 2.32M 29.3M 2.38M 2.33M
Net Debt	893M 5.57M 4.81M 4.44M 4.15M 7.78M 530M 7.9M 52.38M 20.42M 258M 20.92M 20.47M	909M 5.67M 4.9M 4.52M 4.23M 7.92M 539M 8.04M 53.32M 20.79M 262M 21.29M 20.84M